CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week Heart Failure With Preserved Ejection Fraction in the Young Dapagliflozin for treating chronic heart failure with reduced ejection fraction The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients

Clinical TrialSeptember 2019

JOURNAL:J Am Coll Cardiol. Article Link

Health Status after Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients with Aortic Stenosis

SJ Baron, EA Magnuson, the PARTNER 3 Investigators. Keywords: low surgical risk; quality of life

ABSTRACT


BACKGROUND - In patients with severe aortic stenosis (AS) at low surgical risk, treatment with transcatheter aortic valve replacement (TAVR) results in lower rates of death, stroke, and re-hospitalization at 1 year compared with surgical aortic valve replacement; however, the effect of treatment strategy on health status is unknown.

OBJECTIVES - This study sought to compare health status outcomes of TAVR vs. surgery in low-risk patients with severe AS.

METHODS - Between 3/2016 and 10/2017, 1000 low-risk AS patients were randomized to transfemoral TAVR using a balloon-expandable valve or surgery in the PARTNER 3 Trial. Health status was assessed at baseline, 1, 6 and 12 months using the Kansas City Cardiomyopathy Questionnaire (KCCQ), SF-36 and EQ-5D. The primary endpoint was change in KCCQ-Overall Summary (KCCQ-OS) score over time. Longitudinal growth curve modeling was used to compare changes in health status between treatment groups over time.

RESULTS - At 1 month, TAVR was associated with better health status than surgery (mean difference in KCCQ-OS 16.0 points; p<0.001). At 6 and 12 months, health status remained better with TAVR, although the effect was reduced (mean difference in KCCQ-OS 2.6 and 1.8 points respectively; p<0.04 for both). The proportion of patients with an excellent outcome (alive with KCCQ-OS 75 and no significant decline from baseline) was greater with TAVR than surgery at 6 months (90.3% vs. 85.3%; p=0.03) and 12 months (87.3% vs. 82.8%; p=0.07).

CONCLUSIONS - Among low-risk patients with severe AS, TAVR was associated with meaningful early and late health status benefits compared with surgery.